Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultratrace Iobenguane I 131 in Relapsed/Refractory High-Risk Neuroblastoma
NCT00992173Phase 2Withdrawn
- Sponsor
- Molecular Insights Pharmaceuticals
- Start
- Jan 2010
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of Iobenguane I-131 in neuroblastoma, sponsored by Molecular Insights Pharmaceuticals. Primary endpoint: Proportion of patients with complete or partial response. Planned start Jan 2010; status: withdrawn.
02
Drugs
Iobenguane I-131
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT00992173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00992173.